Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience

• Published in: Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki) Vol. 41; no. 1; p. 5
• Main Authors: Trifunovski, Aleksandar, Dimovski, Aleksandar, Dohcev, Sasho, Stavridis, Sotir, Stankov, Oliver, Saidi, Skender, Gjorgjievska, Marija, Popov, Zivko
• Format: Journal Article
• Language: English
• Published: North Macedonia 01.06.2020
• Subjects: Aged; Aged, 80 and over; Biomarkers, Tumor - genetics; Biopsy; Case-Control Studies; Evaluation Studies as Topic; Humans; Male; Middle Aged; Neoplasm Grading - methods; Oncogene Proteins, Fusion - genetics; Prospective Studies; Prostate-Specific Antigen - blood; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Transcriptional Regulator ERG - genetics; TMPRSS2-ERG; diagnose; prostate carcinoma
• ISSN: 1857-8985

Prostate carcinoma is the most frequent malign neoplasm among men with an ever-growing incidence rate. TMPRSS2-ERG fusion transcript leads to the androgen induction of ERG proto-oncogenes expression, representing a high presence of oncogenes alteration among prostate tumour cells. The aim of this research was to detect and evaluate theTMPRSS2-ERG fuse transcript in the tissues of patients with prostate cancer, and establish a base of material of these samples for further genetic examination. The research was a prospective clinical study that involved and focused on random sampling of 101 patients (62 with prostate cancer-study group and 39 with benign changes in the prostate-control group). Real time PCR analysis for detection of the TMPRSS2-ERG fusion transcript in prostate tissue was performed and also data from the histopathology results of tissues were used, as well as data for the level of PSA (prostate-specific antigen) in blood. TMPRSS2-ERG fusion transcript was detected in 20 out of 62 (32.2%) patients with prostate carcinoma and among no patients with benign changes whatsoever. There were no significant differences between patients with/without detected TMPRSS2-ERG fusion related to Gleason score. Among 50%, in the study group this score was greater than 7 per/for Median IQR=7 (6-8). Significant difference was recognized, related to the average value of PSA in favour of significantly higher value of PSA in the study group with prostate cancer, but there was also no significant difference between samples with prostate cancer who were with/without detected TMPRSS2-ERG fusion transcript related to PSA level. The results from this research are in accordance with the values and results from analyses done in several research centres and oncological institutes. The positive findings in small scale studies encourage the implementation of larger scale studies that will be enriched with results of genetic transcript in blood and urine and will define the positive diagnostic meaning of the TMPRSS-ERG fusion transcript.